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The SF-36 was converted into a utility using the preference-based SF-6D. Clinical 
outcomes such European League Against Arthritis (EULAR) Disease Activity Score 
(DAS), joint counts and laboratory measures were also recorded. We calculated single 
index utility scores from the preference-based instruments using UK population norms. 
We used regression analysis and correlation coefﬁcients to compare relationships 
between the Quality of Life (QoL) outcomes and also the clinical outcomes and 
between observed and mapped utility scores. RESULTS: There was a signiﬁcant dif-
ference between the mapped and observed EQ-5D and SF-6D. Overall the mapped 
utilities produced higher values than the actual observed scores. The mean change in 
utility due to treatment is greater with the EQ-5D for both mapped and observed 
utilities. A greater change was seen in the PsA group. CONCLUSIONS: We present 
the different results produced when using mapped utility scores and directly obtained 
scores. We have highlighted the problems associated with deriving utilities from non 
preference-based instruments and the differences in utilities when calculated using 
different measures. While these methods do offer alternatives for researchers when 
performing cost utility analysis they remain suboptimal to the direct method.
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OBJECTIVES: To test the comprehension of the FMBA© in France, Germany and 
Spain. METHODS: The FMBA© was tested to assess ease of comprehension, cultural 
equivalence, clarity, wording and acceptability of the structure and content to patients. 
The test version contained 79 items grouped into 7 sections measuring burden of 
ﬁbromyalgia on patients’ daily lives, developed simultaneously in French, German, 
Spanish and UK English. These sections evaluate Pain, Physical Impact, Impact on 
daily activities, Social Impact, Work Impact, Psychological Impact, Relationship to 
doctors and treatment, and One general item. Sixteen ﬁbromyalgia patients were 
interviewed in France, Germany and Spain. UK comprehension tests are currently 
under way. Based on test results and deliberation with ﬁbromyalgia experts, changes 
were made to the French, German, Spanish and UK English versions of the question-
naire during an international harmonisation meeting. RESULTS: Patients’ overall 
comprehension of the questionnaire was good. The comprehension tests identiﬁed 
problematic items, and suggestions for deletions or rewording. Seventeen items were 
deleted for reasons such as; lack of conceptual clarity e.g. “I have pain that changes 
from one moment to the next” not clear between location and intensity; items con-
sidered conceptually too close e.g. “I get tired for no reason” deleted because too close 
to “I lack energy” and “I get tired easily”; and wording too strong” e.g. “I feel handi-
capped”. The answer choices were also modiﬁed to ensure cultural acceptance. The 
pilot version of the FMBA© contains 62 items divided into 7 sections. CONCLU-
SIONS: The FMBA© is a questionnaire that assesses the functional impact and burden 
of ﬁbromyalgia on patients’ daily lives. The FMBA© will allow the consequences of 
FM on patients to be more widely recognised. A validation study is to be undertaken 
to validate psychometric properties and scoring of the questionnaire.
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OBJECTIVES: To develop a European screening tool to help primary care physicians 
(PCPs) identify ﬁbromyalgia (FM) patients in general practice. METHODS: A Euro-
pean multidisciplinary expert group was set up to provide clinical expertise and iden-
tify key issues around FM detection. A literature review and focus groups conducted 
with French (FR), German (DE) and English (UK) clinicians provided an overview of 
the knowledge in FM and of clinicians’ awareness and experience. Psychologists then 
performed face-to-face exploratory interviews with FM patients (FR, DE and UK, n 
 29) to understand their attitudes and perceptions of the disease. Based on the ﬁnd-
ings, items were simultaneously generated in FR, UK and DE. The resulting tool was 
comprehension tested with FM-diagnosed or -suspected patients (n  3 and n  2 in 
each country, respectively), and modiﬁed based on results. Its acceptability and appli-
cability was then assessed in real-life conditions in general practice. RESULTS: The 
tool content deﬁned using literature review, health professional and patient input had 
high consistency regardless of the source from which it was extracted. Factors found 
that may contribute to the early detection of FM included elements of FM deﬁnition, 
patient characteristics, personal and medical history, quality of life, attitude and per-
sonality, associated symptoms and inﬂuencing factors. The resulting pilot version of 
the FM screening tool includes 14 questions assessing patients’ pain, fatigue, associ-
ated symptoms, impact on patients’ everyday life, personal history, and attitudes 
towards their symptoms. Face validity and feasibility have been conﬁrmed by PCPs 
and patients when administered in general practice. CONCLUSIONS: In addition to 
the symptomatic picture, FM detection requires the assessment of multiple factors 
including patient past history and characteristics, impact of FM on patients’ daily life, 
and situations/factors affecting patients’ condition. By capturing each of these factors, 
the European FM screening tool will help PCPs identify potential FM patients. Quan-
titative validation of the tool is underway.
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OBJECTIVES: Health related quality of life (HRQoL) is an important issue to evaluate 
outcomes after health interventions. The aim of this study was to study construct 
validity and responsiveness of the OsteoArthritis of Hip and Knee Quality of Life 
questionnaire (OAKHQOL), a disease-speciﬁc HRQoL for osteoarthritis of the lower 
limb. METHODS: OAKHQOL is a self administered questionnaire and has 43 items 
and ﬁve dimensions: physical activities (16), pain (4), mental health (13), social 
support (4) and social functioning (3). There are 3 independent items about relation-
ships, sexual activities and professional life. The score range from 0 (worst) to 100 
(best health). Patients were recruited patients from the waiting list to undergo joint 
replacement. The internal consistency was measured by Cronbach´s alpha (771 
patients). The test-retest reliability (413 stable patients who fulﬁlled the questionnaire 
two times) was measured by Intraclass correlation coefﬁcient (ICC). The responsive-
ness was evaluated by means of standardized effect size (SES) and standardized 
response mean (SRM) six months post surgical replacement. RESULTS: Cronbach´s 
alpha were all higher than 0.8 but in social activities dimension (0.64). Regarding 
test-retest reliability the ICCs were higher than 0.75 but in the social activities (0.4) 
and social support (0.4) dimensions. Finally, responsiveness parameters were: physical 
dimension (SES  1.26; SRM  0.89); pain (SES  1.37; SRM  0.94); mental health 
(SES  0.65; SRM  0.56). CONCLUSIONS: These results support the validity and 
responsiveness of the Spanish version of the OAKHQOL a disease speciﬁc HRQoL 
questionnaire to be used in patients with osteoarthritis of the lower limb and surgical 
management.
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OBJECTIVES: Development of validated patient-reported outcome (PRO) measures 
has the potential to positively impact scientiﬁc research and patient management. To 
date, the speciﬁc issues and symptoms most relevant to DM1 patients’ health related 
quality-of-life (HRQOL) have not been systematically assessed. Our goal is to identify 
those aspects of HRQOL that are most important to patients with DM1, a neuromus-
cular condition with multisystemic organ dysfunction. METHODS: We conducted 
in-depth individual patient interviews with twenty genetically conﬁrmed, adult, DM1 
patients representing varied levels of disability. Each interview focused on identifying 
the DM1 issues that have the greatest impact on patient HRQOL. Each interview was 
recorded, transcribed, coded, and analyzed using a qualitative framework technique, 
triangulation, and three investigator consensus approach. RESULTS: A total of 1175 
direct quotes were coded resulting in 223 like themes. These themes were subsequently 
categorized into 7 subdomains representing physical, mental, and social aspects of 
DM1 HRQOL. A disease-speciﬁc HRQOL conceptual model was created for DM1 
representing the most relevant symptomatic and psychosocial issues in this population. 
Categories in this model included: 1) mobility and ambulation/ ﬁne motor and upper 
extremity dysfunction; 2) emotional distress; 3) cognitive impairment; 4) social role 
limitations; 5) social role dissatisfaction; 6) activity impairment; and, 7) DM1-speciﬁc 
symptoms of: sleep disturbance, fatigue, pain/myotonia, gastrointestinal dysfunction, 
central sensory impairment, and communication difﬁculties. Difﬁculty with ambula-
tion was the most frequently mentioned issue by our sample of patients. CONCLU-
SIONS: There are multiple themes and symptoms, some previously underrecognized, 
that play a key role in DM1 patient reported HRQOL. These issues must be carefully 
examined in order to develop a representative disease-speciﬁc conceptual model and 
PRO measurement tool. The development of such an instrument has the potential to 
improve DM1 clinical care and maximize the impact and relevance of future DM1 
clinical research.
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OBJECTIVES: The Rheumatoid Arthritis Quality of Life scale (RAQoL) is the ﬁrst 
true QoL measure for RA and is widely used in clinical practice and trials. The scale 
has good psychometric properties and has been shown to be responsive to changes in 
disease severity. The objective of the study was to adapt the RAQoL for USA, Mexico, 
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Argentina, Belgium (French and Flemish), France, Romania, Czech Republic, Slovakia, 
Poland and Russia. METHODS: The adaptation in each country required 3 stages: 
Translation, cognitive debrieﬁng and a validation survey. The translation process 
adopted the dual panel (bilingual followed by lay panel) methodology to ensure the 
‘naturalness’ of language. Cognitive-debrieﬁng interviews assessed face and content 
validity with local RA patients. The validation survey tested the psychometric proper-
ties of the new scales and included the Nottingham Health Proﬁle (NHP) as a com-
parator. RESULTS: The sample size for France was inadequate to test its psychometric 
properties. Mean scores on the new versions of the RAQoL ranged from 10.7 to 15.7 
(maximum possible  30). Internal consistency ranged from 0.90–0.97 and test-retest 
reliability from 0.85–0.99 with 7 countries above 0.90. Scores were related to self-
perceived severity in all countries, reaching signiﬁcance in 7 out of 10 countries and 
were signiﬁcantly related to self-perceived general health in all countries. Mean cor-
relations with NHP sections were highest (as expected) with energy level, pain and 
physical mobility (average correlations 0.71–0.74) and lowest with emotional reac-
tions, sleep disturbance and social isolation (average correlations 0.50–0.67). CON-
CLUSIONS: The present study indicates that (with the exception of France which 
requires additional validation data) the new language versions of the RAQoL meet 
the standards of the original UK version and the other 8 existing versions. The new 
instruments represent valid and reliable tools for measuring QoL in international 
clinical trials in RA.
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OBJECTIVES: To assess the impact of psoriatic arthritis on the quality of life of 
patients due to the illness. METHODS: An observational study was designed recruit-
ing 287 patients from 18 Spanish centers to assess psoriatic arthritis patients’ quality 
of life. Data about the demographic characteristics of the sample were collected. 
Measures of the severity of the psoriatic arthritis were: 1) Psoriasis Area and Severity 
Illness (PASI scores 0–72, from low to high severity of psoriasis); 2) Number of painful 
or inﬂamed joints; 3) Health Assessment Questionnaire (HAQ; assessment of illness 
impact in different types of activities). Assessment of health-related quality of life 
(HRQL) was performed using: 1) Quality of life questionnaire EuroQol-5D (EQ-5D 
scores 0–3; higher scores are related to worse HRQL) and its Visual Analogue Scale 
(VAS scores 0–100; higher scores represent a best HQRL); and 2) Quality of life 
questionnaire Short Form-36 (SF-36 scores 0–100; higher scores are related to best 
HRQL). Frequency distribution, means and SD of the data were shown. RESULTS: 
The majority of cases were males (55.7%) and the mean age was 52.40 o 12.53 years. 
Mean number of inﬂamed joints was 2.62 o 4.06 and mean number of painful joints 
was 4.97 o 6.85. Mean value of PASI scores was 3.73 o 5.83. Biologic drugs were 
used in 25% of the patients. Mean values in the domains of EQ-5D with a worst 
self-assessment were: pain, 1.86 o 0.56 and usual activities, 1.52 o 0.55. Mean score 
of VAS was 60.41 o 20.08. Domains in SF-36 where the patients report a worst 
functioning were: physic role, 50.76 o 43.43, body pain, 49.35 o 25.69, general health, 
43.78 o 19.75, vitality 50.01 o 22.58 and physical summary component, 37.88 o 
10.87. This tendency is related to the results shown in HAQ questionnaire where more 
than 40% of patients have some difﬁculties in daily/usual activities. CONCLUSIONS: 
Psoriatic arthritis is associated with an impairment of HRQL that is mainly character-
ized by body pain and a worst functioning in daily activities.
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OUTCOME IN PATIENTS WITH MONOSEGMENTAL LUMBAR FUSION?
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OBJECTIVES: Obesity is often considered as a risk-factor for higher complication rates 
and worse clinical outcome of fusion surgery in the lumbar spine and is therefore 
sometimes not performed in obese patients despite relative indication for surgery. The 
goal of this study was to evaluate whether BMI is a predictive factor for clinical 
outcome after monosegmental fusion surgery in the lumbar spine. METHODS: The 
present study is a retrospective analysis of prospectively collected data in a consecutive 
series of patients. Between April 2002 and April 2007, a total of 467 patients under-
went monosegmental lumbar fusion in a single spine center. Preoperatively, at 6 weeks 
and at 1 year follow-up, SF36 and Oswestry-Disability-Index scores were collected. 
We excluded patients who underwent surgery due to infections, tumor and trauma, as 
well as revision surgeries, and all patients with incomplete datasets, so that 223 patients 
were included in the study. Of those patients, variables considered as risk-factors like 
age, BMI and the presence of comorbidities like diabetes mellitus were assessed from 
the medical records. A multiple regression model for those parameters and clinical 
outcome was cretated. RESULTS: In an unadjusted model, BMI did not at all predict 
clinical outcome, in a multivariate model adjusted for baseline outcome values of SF36, 
Oswestry-Disability index and age, a slight trend towards negative correlation between 
BMI and outcome could be shown (p  0.06) at one-year follow-up. CONCLUSIONS: 
This study suggests that BMI alone is not a good predictor of clinical outcome of 
monosegmental lumbar fusion one year after surgery and that therefore this kind 
of surgery should not be withheld from patients only because of obesity.
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OBJECTIVES: The aim was to study differences in baseline scores of two health 
related quality of life (HRQOL) hip/knee osteoarthritis questionnaires, between dif-
ferent anxiety levels. METHODS: We applied questionnaires in a sample before 
intervention. The questionnaires were OAKHQOL, score from 0 (the worst) to 100 
(the best); WOMAC with a range from 0 (the best) to 100 (the worst); and one item 
about anxiety which grouped patients into 5 levels. We categorized into 3 groups: 
“nothing/a little anxious”, “moderately anxious” and “very/extremely anxious”. We 
analyzed differences through analysis of variance with Scheffé’s test. RESULTS: 729 
patients were included. The anxiety groups were: 411 “noting/a little anxious”, 218 
“moderately anxious” and 100 “very/extremely anxious”. We found worse scores as 
anxiety level increase and statistically signiﬁcant differences (p  0.001) in nearly all 
OAKHQOL dimensions. In physical activity, mean (DS) of 31.44 (20.87) in the lowest 
group, 22.91(15.19) in “moderately”, and 14.56(13.34) in “very/extremely” group; 
in pain we observed 36.53(25.45) in “noting/little”, 24.96(19.61) in “moderately”, 
and 17.23(16.91) in “very/extremely” group; in mental health, 61.39(20.63) in the 
lowest group, 41.30(18.38) in moderate, and 24.75(13.05) in the highest group; and 
in social activities we observed differences (p  0.002) between the lowest (mean 59.07 
(26.84)) and the highest anxiety groups, (49.59 (26.05)). Social support didn’t show 
any relation. In WOMAC there were differences (p  0.001) amongst the three anxiety 
groups. In pain, the baseline score was 47.73 (19.24) in “nothing/little group, 55.23 
(16.77) in “moderately” and 63.99 (18.38) in “very/extremely anxious”; in stiffness, 
were 47.04 (24.29) in the lowest group, 53.88 (21.70) in moderate and 61.25 (26.32) 
in the highest anxiety group; ﬁnally, the baseline data in functionality were 52.58 
(20.36) in the lowest group, 60.29 (16.98) in moderate, and 69.44 (18.56) in the 
highest anxiety group. CONCLUSIONS: These ﬁndings show an association between 
anxiety levels and HRQOL baseline scores.
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OBJECTIVES: Decision-making in Rheumatoid arthritis (RA) is often based on non-
speciﬁc disease outcome measures as improvement in Health-Related Quality of Life 
(HRQoL). It is therefore crucial that HRQoL discriminate across RA severity. Several 
utility measures have been validated, from either direct (i.e. standard gamble) or 
indirect methods (i.e. EuroQol [EQ-5D], Brazier’s Short Form-6D [SF-6D], VAS-
QoL). These utility values are commonly mapped to the Health Assessment Question-
naire (HAQ) to discriminate HRQoL across different RA disease states. We evaluated 
whether the EQ-5D, SF-6D and the VAS would lead to similar utility values and dis-
criminate across disease severity among a cohort of RA patients in Portugal. 
METHODS: Using a biannual cohort of Portuguese RA patients since 2003 (NDB-
Portugal), a total of 713 patients were included in this study. Utility measures were 
assigned to each level of HAQ using 0.50 intervals. Mean and standard deviation 
utility measures were calculated using the last observation per patient. RESULTS: 
Utilities decreased as HAQ scores worsened. The mean utility values of patients varied 
signiﬁcantly depending on the measurement method. Mean utility measured using the 
EuroQOL-5D was 0.48 and mean HAQ was 1.4 (0–3, 3 corresponding to the worst 
disability). Utilities per HAQ intervals using SF-6D did not differentiate across levels 
of disease severity (HAQ 0–0.5  0.67 ; HAQ 2.5–3  0.55). The EQ-5D differentiated 
more across the severity groups (HAQ 0–0.5  0.83 ; HAQ 2.5–3  0.08). VAS-Qol 
only discriminated marginally (HAQ 0–0.5  0.74 ; HAQ 2.5–3  0.45). CONCLU-
SIONS: In a cohort of Portuguese RA patients, different utility measurement in- 
struments resulted in different utility scores. Furthermore, not all utility measures 
discriminated across disease severity. Decision-making relying on these measures, the 
results of this analysis show that different utility measurement instruments may lead 
to signiﬁcantly different results. This may lead to potentially different resource alloca-
tion decisions.
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OBJECTIVES: The aim of this study was to determine the reliability and validity of 
the Social Functioning Scale (SFS) for the Turkish MSDs (Musculoskeletal disorders) 
